文献速递肝病消化道肿瘤与早癌

非选择性β受体阻滞剂与肝硬化患者肝细胞癌风险降低相关

Nonselective beta-blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States.
PubMed 文献 · Aliment Pharmacol Ther · 2021-07-05

结果显示非选择性β受体阻滞剂与肝细胞癌风险显著降低相关,卡维地洛风险比0.61(95%CI 0.51-0.73)。

要点

  • 非选择性β受体阻滞剂与肝硬化患者肝细胞癌风险显著降低相关。
  • 卡维地洛、纳多洛尔、普萘洛尔均显示风险降低,卡维地洛风险比最低。
  • 合并并发症及非酒精性肝硬化亚组中非选择性β受体阻滞剂同样降低肝细胞癌风险。

核心结论

  • 非选择性β受体阻滞剂(包括卡维地洛)与肝硬化患者肝细胞癌风险显著降低相关。

主要发现

  • 100个月累积肝细胞癌发生率:卡维地洛11.24% vs 无β受体阻滞剂15.69%,纳多洛尔27.55% vs 32.11%,普萘洛尔26.17% vs 28.84%(P值均<0.0001)。
  • 倾向性评分匹配后多变量Cox分析风险比:卡维地洛0.61(95%CI 0.51-0.73),纳多洛尔0.74(95%CI 0.63-0.87),普萘洛尔0.75(95%CI 0.66-0.84)。
  • 亚组分析显示非选择性β受体阻滞剂在合并并发症的肝硬化及非酒精性肝硬化中降低肝细胞癌风险。

临床怎么用

  • 对于肝硬化患者,使用非选择性β受体阻滞剂(包括卡维地洛)可能与肝细胞癌风险降低相关,但需结合个体适应症评估。

局限性

  • 本研究为回顾性队列研究,可能存在未测量的混杂因素,且需未来随机对照研究验证不同非选择性β受体阻滞剂预防肝细胞癌的最佳选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous studies have demonstrated an association between nonselective beta-blockers (NSBBs) and lower risk of hepatocellular carcinoma (HCC) in cirrhosis. However, there has been no population-based study investigating the risk of HCC among cirrhotic patients treated using carvedilol. AIMS: To determine the risk of HCC among cirrhotic patients with NSBBs including carvedilol. METHODS: This retrospective cohort study utilised the Cerner Health Facts database in the United States from 2000 to 2017. Kaplan-Meier estimate, Cox proportional hazards regression, and propensity score matching (PSM) were used to test the HCC risk among the carvedilol, nadolol, and propranolol groups compared with no beta-blocker group. RESULTS: The final cohort comprised 107 428 eligible patients. The 100-month cumulative HCC incidence of NSBBs was significantly lower than the no beta-blocker group (carvedilol (11.24%) vs no beta-blocker (15.69%), nadolol (27.55%) vs no beta-blocker (32.11%), and propranolol (26.17%) vs no beta-blocker (28.84%) (P values < 0.0001). NSBBs were associated with a significantly lower risk of HCC (Hazard ratio: carvedilol 0.61 (95% CI 0.51-0.73), nadolol 0.74 (95% CI 0.63-0.87), propranolol 0.75 (95% CI 0.66-0.84) after PSM in the multivariate cox analysis. In subgroup analysis, NSBBs reduced the risk of HCC in cirrhosis with complications and non-alcoholic cirrhosis. CONCLUSIONS: NSBBs, including carvedilol, were associated with a significantly decreased risk of HCC in patients with cirrhosis when compared with no beta-blocker regardless of complications status. Future randomised-controlled studies comparing the incidence of HCC among NSBBs should elucidate which NSBB would be the best option to prevent HCC in cirrhosis.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Wijarnpreecha K, Li F, Xiang Y, et al. Nonselective beta-blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States. Aliment Pharmacol Ther. 2021. PMID: 34224163. doi:10.1111/apt.16490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。